Skip to content
★ Sign in to follow
GS

Genextra S.p.A.

Related company / holding
Intercept Pharmaceuticals, Inc.
Total declarations
15
Company
1
▲ Purchases (1 ops.)
€20.3M
▼ Sales (10 ops.)
€313.6M

Latest filing published 17 Aug 2020 for Intercept Pharmaceuticals, INC., €3.7M.

Filing timeline

BuySale
Genextra S.p.A.

Insider track record

Disclosed buys
1
Disclosed sells
10
Signal history

Closed purchases

Market purchases
1

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Genextra S.p.A.: trading record in brief

Genextra S.p.A. discloses dealings in Intercept Pharmaceuticals, Inc. to SEC (Form 4). Between 16 October 2012 and 17 August 2020, the trades on record add up to 15 filings.

Both buying and selling appear: 1 purchase worth €20.3M, against 10 sales worth €313.6M. On balance, insiders were net sellers of €293.3M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant. In 2020 alone, the filings show no purchases and 5 sales.

The record was last updated on 17 August 2020 with an open-market sale (€3.7M) in Intercept Pharmaceuticals, Inc. The latest purchase dates back some time: it was published 3,136 days ago, on 9 April 2018. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Genextra S.p.A.

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations9 total

11 of 9 declarations